Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation

Table 1 Baseline characteristics

Parameters	DXM 40 mg treatment (n = 48)	DXM 20 mg treatment (n = 48)	P value
Age, yr	69.0 ± 7.2	70.0 ± 8.4	0.646
Gender (male/female)	26/22	30/18	0.408
DS stage			0.544
I	1 (2%)	1 (2%)
II	6 (12.5%)	10 (20.8)
III	41 (85.5%)	37 (77.2%)
ISS stage			0.791
I	8 (16.7%)	10 (20.8)
II	22 (45.8%)	19 (39.6%)
III	18 (38.5)	19 (39.6%)
CRP	13 (27.1%)	16 (33.3%)	0.461
HGB	68.0 ± 13.4	67.0 ± 14.7	0.525
Platelet	13 (27.1%)	11 (22.9%)	0.637
t(6;14)	0	2 (4.2%)	0.093
t(11;14)	7 (14.6%)	8 (16.7%)	0.779
ALT	4 (8.3%)	2 (4.2%)	0.399
AST	7 (14.6%)	6 (12.5%)	0.765
LDH	9 (18.6%)	10 (20.8)	0.798
Cr	20 (41.7%)	16 (33.3%)	0.399
UA	17 (35.4)	12 (25%)	0.266
Treatment			0.147
VRD	38 (79.2%)	40 (83.3%)
PCD	10 (20.8)	6 (12.5%)
PD	0	2 (4.2%)

VRD: Bortezomib, lenalidomide, and dexamethasone; VCD: Regimens, 16 patients received bortezomib, cyclophosphamide, and dexamethasone; CRP: Catabolite activator protein; HGB: Hemoglobin; UA: Urea nitrogen; Cr: Creatinine; LDH: Lactate dehydrogenase.